Cilcare key facts
- Operator of a biotechnology company intended to deliver treatment of hearing disorders.
- It has raised $47.0M; the latest was Later Stage VC ($42.4M) in Dec 2024.
- Notable investors include Bpifrance, Sofilaro, SPRIM Global Investments, Capitole Angels, Aris (Other Financial Services) — 13 tracked in total.
- Status: Privately Held (backing).
Who backs Cilcare
13+- ·The complete investor list: 13 names
- ·Watch Cilcare: the Monday email on marks, rounds and moves
Cilcare funding rounds
No funding rounds for Cilcare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Cilcare investors
13 investors are on record for Cilcare, including Bpifrance, Sofilaro, SPRIM Global Investments and Capitole Angels.
About Cilcare
Operator of a biotechnology company intended to deliver treatment of hearing disorders. The company's technology utilizes auditory sciences for the early definition, detection, and treatment of synaptopathy in neurocognitive and inflammatory diseases, enabling doctors to provide effective treatments to patients suffering from ear diseases.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2014
- Employees
- 59
- Website
- cilcare.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Cilcare doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.